Therapeutic vaccines in metastatic castration-resistant prostate cancer: principles in clinical trial design

Bibliography

• Roehl KA, Han M, Ramos CG, Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 2004;172:910-4
   PubMed Web of Science ®Google Scholar
• D'Amico AV, Whittington R, Malkowicz SB, Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-74
   PubMed Web of Science ®Google Scholar
• Zelefsky MJ, Chan H, Hunt M, Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol 2006;176:1415-9
   PubMed Web of Science ®Google Scholar
• Han M, Partin AW, Zahurak M, Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003;169:517-23
   PubMed Web of Science ®Google Scholar
• Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA 2005;294:238-44
   PubMed Web of Science ®Google Scholar
• Tannock IF, de Wit R, Berry WR, Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12
   PubMed Web of Science ®Google Scholar
• Petrylak DP, Tangen CM, Hussain MH, Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20
   PubMed Web of Science ®Google Scholar
• Coffey DS, Isaacs JT. Prostate tumor biology and cell kinetics–theory. Urology 1981;17:40-53
   PubMed Web of Science ®Google Scholar
• Rhodes DR, Barrette TR, Rubin MA, Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res 2002;62:4427-33
   PubMed Web of Science ®Google Scholar
• Fong L, Small EJ. Immunotherapy for prostate cancer. Semin Oncol 2003;30:649-58
   PubMed Web of Science ®Google Scholar
• Chakraborty NG, Stevens RL, Mehrotra S, Recognition of PSA-derived peptide antigens by T cells from prostate cancer patients without any prior stimulation. Cancer Immunol Immunother 2003;52:497-505
   PubMed Web of Science ®Google Scholar
• Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991;145:907-23
   PubMed Web of Science ®Google Scholar
• Madan RA, Gulley JL, Arlen PM. PSA-based vaccines for the treatment of prostate cancer. Expert Rev Vaccines 2006;5:199-209
   PubMed Web of Science ®Google Scholar
• Murphy GP, Elgamal AA, Su SL, Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. Cancer 1998;83:2259-69
   PubMed Web of Science ®Google Scholar
• Wright GL Jr, Grob BM, Haley C, Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 1996;48:326-34
   PubMed Web of Science ®Google Scholar
• Veeramani S, Yuan TC, Chen SJ, Cellular prostatic acid phosphatase: a protein tyrosine phosphatase involved in androgen-independent proliferation of prostate cancer. Endocr Relat Cancer 2005;12:805-22
   PubMed Web of Science ®Google Scholar
• Vihko P, Virkkunen P, Henttu P, Molecular cloning and sequence analysis of cDNA encoding human prostatic acid phosphatase. FEBS Lett 1988;236:275-81
   PubMed Web of Science ®Google Scholar
• Bera TK, Das S, Maeda H, NGEP, a gene encoding a membrane protein detected only in prostate cancer and normal prostate. Proc Natl Acad Sci USA 2004;101:3059-64
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Nagato T, Oikawa K, Recognition of prostate and breast tumor cells by helper T lymphocytes specific for a prostate and breast tumor-associated antigen, TARP. Clin Cancer Res 2005;11:3869-78
   PubMed Web of Science ®Google Scholar
• Small EJ, Fratesi P, Reese DM, Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000;18:3894-903
   PubMed Web of Science ®Google Scholar
• Rini BI. Technology evaluation: APC-8015, dendreon. Curr Opin Mol Ther 2002;4:76-9
   PubMed Web of Science ®Google Scholar
• Patel PH, Kockler DR. Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer. Ann Pharmacother 2008;42:91-8
   PubMed Web of Science ®Google Scholar
• Hodge JW, Sabzevari H, Yafal AG, A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res 1999;59:5800-7
   PubMed Web of Science ®Google Scholar
• Correale P, Walmsley K, Nieroda C, In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J Natl Cancer Inst 1997;89:293-300
   PubMed Web of Science ®Google Scholar
• Correale P, Walmsley K, Zaremba S, Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide. J Immunol 1998;161:3186-94
   PubMed Web of Science ®Google Scholar
• Madan RA, Arlen PM, Mohebtash M, Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opin Investig Drugs 2009;18:1001-11
   PubMed Web of Science ®Google Scholar
• Essajee S, Kaufman HL. Poxvirus vaccines for cancer and HIV therapy. Expert Opin Biol Ther 2004;4:575-88
   PubMed Web of Science ®Google Scholar
• Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci USA 1996;93:11341-8
   PubMed Web of Science ®Google Scholar
• Hodge JW, Grosenbach DW, Rad AN, Enhancing the potency of peptide-pulsed antigen presenting cells by vector-driven hyperexpression of a triad of costimulatory molecules. Vaccine 2001;19:3552-67
   PubMed Web of Science ®Google Scholar
• Zhu M, Terasawa H, Gulley J, Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells. Cancer Res 2001;61:3725-34
   PubMed Web of Science ®Google Scholar
• Palena C, Zhu M, Schlom J, Tsang KY. Human B cells that hyperexpress a triad of costimulatory molecules via avipox-vector infection: an alternative source of efficient antigen-presenting cells. Blood 2004;104:192-9
   PubMed Web of Science ®Google Scholar
• Ward JE, McNeel DG. GVAX: an allogeneic, whole-cell, GM-CSF-secreting cellular immunotherapy for the treatment of prostate cancer. Expert Opin Biol Ther 2007;7:1893-902
   PubMed Web of Science ®Google Scholar
• Cell Genesys Takeda Announce Termination of Collaboration Agreement for GVAX Immunotherapy for Prostate Cancer. Cell Genesys press release. San Francisco, California and Osaka, Japan. 2008. Available at: http://phx.corporate-ir.net/preview/phoenix.zhtml?c=98399&p=irol-newsArticle&ID=1231960&highlight= [Last accessed 18 September 2009]
   Google Scholar
• Eaton JD, Perry MJ, Nicholson S, Allogeneic whole-cell vaccine: a phase I/II study in men with hormone-refractory prostate cancer. BJU Int 2002;89:19-26
   PubMedGoogle Scholar
• von Mehren M, Arlen P, Gulley J, The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin Cancer Res 2001;7:1181-91
   PubMed Web of Science ®Google Scholar
• Fu T, Shen Y, Fujimoto S. Tumor-specific CD4+ suppressor T-cell clone capable of inhibiting rejection of syngeneic sarcoma in A/J mice. Int J Cancer 2000;87:680-7
   PubMed Web of Science ®Google Scholar
• Ghiringhelli F, Larmonier N, Schmitt E, CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 2004;34:336-44
   PubMed Web of Science ®Google Scholar
• Piccirillo CA, Shevach EM. Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol 2001;167:1137-40
   PubMed Web of Science ®Google Scholar
• Woo EY, Yeh H, Chu CS, Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 2002;168:4272-6
   PubMed Web of Science ®Google Scholar
• Teicher BA. Transforming growth factor-beta and the immune response to malignant disease. Clin Cancer Res 2007;13:6247-51
   PubMed Web of Science ®Google Scholar
• Muller AJ, Prendergast GC. Indoleamine 2,3-dioxygenase in immune suppression and cancer. Curr Cancer Drug Targets 2007;7:31-40
   PubMed Web of Science ®Google Scholar
• Madan RA, Gulley JL, Schlom J, Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy. Clin Cancer Res 2008;14:4526-31
   PubMed Web of Science ®Google Scholar
• Small E, Schellhammer P, Higano C, Immunotherapy (APC8015) for androgen independent prostate cancer (AIPC): final survival data from a phase 3 randomized placebo-controlled trial [abstract]. ASCO Prostate Cancer Symposium 2005;64
   Google Scholar
• Madan R, Gulley J, Dahut W, Overall survival (OS) analysis of a phase II study using a pox viral-based vaccine, PSA-TRICOM, in the treatment of metastatic, castrate-resistant prostate cancer (mCRPC): implications for clinical trial design [abstract]. ASCO Meeting Abstracts 2008;3005
   Google Scholar
• Pound CR, Partin AW, Eisenberger MA, Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-7
   PubMed Web of Science ®Google Scholar
• Freedland SJ, Humphreys EB, Mangold LA, Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005;294:433-9
   PubMed Web of Science ®Google Scholar
• Flutamide with or without vaccine therapy in treating patients with nonmetastatic prostate cancer. Clinical trials.gov Bethesda, Maryland, National Institutes of Health 2009; Available at: http://www.clinicaltrials.gov/ct2/show/NCT00450463?term=gulley&rank=10 [Last accessed 18 September 2009]
   Google Scholar
• Halabi S, Small EJ, Kantoff PW, Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003;21:1232-7
   PubMed Web of Science ®Google Scholar
• Small EJ, Schellhammer PF, Higano CS, Placebo-controlled Phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006;24:3089-94
   PubMed Web of Science ®Google Scholar
• Small E, Rini B, Higano C, randomized, placebo-controlled phase III trial of APC8015 in patients with androgen-independent prostate cancer (AiPCa) [abstract]. ASCO Annual Meeting 2003;1534
   Google Scholar
• Higano C, Saad F, Somer B, A phase III trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer (CRPC) [abstract]. ASCO Genitourinary Cancers Symposium 2009;LBA150
   Google Scholar
• Schuster S, Neelapu S, Gause B, Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: Phase III clinical trial results. J Clin Oncol 2009;27(18S):2
   PubMedGoogle Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16
   PubMed Web of Science ®Google Scholar
• Therasse P, Eisenhauer EA, Verweij J. RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer 2006;42:1031-9
   PubMed Web of Science ®Google Scholar
• Gulley JL, Arlen PM, Tsang KY, Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin Cancer Res 2008;14:3060-9
   PubMed Web of Science ®Google Scholar
• Jones RL, Cunningham D, Cook G, Ell PJ. Tumour vaccine associated lymphadenopathy and false positive positron emission tomography scan changes. Br J Radiol 2004;77:74-5
   PubMed Web of Science ®Google Scholar
• Loveland BE, Zhao A, White S, Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma. Clin Cancer Res 2006;12:869-77
   PubMed Web of Science ®Google Scholar
• Kantoff P, Glode L, Tannenbaum S, Randomized, double-blind, vector-controlled study of targeted immunotherapy in patients (pts) with hormone-refractory prostate cancer (HRPC) [abstract]. J Clin Oncol 2006;24(18S):2501
   Google Scholar
• PROSTVAC–promising Phase II results lead to Phase III in 2010. Kvistgård, Denmark: Bavarian Nordic 2009; Available at: http://www.bavarian-nordic.com/prostvac [Last accessed 18 September 2009]
   Google Scholar
• Cellular, Tissue and Gene Therapies Advisory Committee: Sipuleucel-T Briefing Document. Bethesda Maryland, USFDA, 2007; Available at: http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4291B1_01.pdf [Last accessed 18 September 2009]
   Google Scholar
• AUA Late-Breaking Science Forum: Review of the Provenge Trial Accessed: May 2009; Available from: http://www.aua2009.org/program/lbsciforum.asp
   Google Scholar
• Garnett CT, Schlom J, Hodge JW. Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement. Clin Cancer Res 2008;14:3536-44
   PubMed Web of Science ®Google Scholar
• Gribben JG, Ryan DP, Boyajian R, Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin Cancer Res 2005;11:4430-6
   PubMed Web of Science ®Google Scholar
• Antonia SJ, Mirza N, Fricke I, Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res 2006;12:878-87
   PubMed Web of Science ®Google Scholar
• Petrylak D. Defining the optimal role of immunotherapy and chemotherapy: advanced prostate cancer patients who receive sipuleucel-T (Provenge) followed by docetaxel derive greatest survival benefit [abstract]. Chemotherapy Foundation Symposium 14th Annual Meeting 2006; N/A
   Google Scholar
• Higano CS, Corman JM, Smith DC, Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer 2008;113:975-84
   PubMed Web of Science ®Google Scholar
• GVAX Immunotherapy for Prostate Cancer. San Francisco, California: Cell Genesys 2009. Available at: http://www.cellgenesys.com/view.cfm/20/GVAX-Immunotherapy-for-Prostate-Cancer [Last accessed 18 September 2009]
   Google Scholar
• Small E, Demkow T, Gerritsen W, A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC) [abstract]. ASCO Genitourinary Cancers Symposium 2009;7
   Google Scholar
• Sakaguchi S, Sakaguchi N, Asano M, Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995;155:1151-64
   PubMed Web of Science ®Google Scholar
• Morse MA, Clay TM, Mosca P, Lyerly HK. Immunoregulatory T cells in cancer immunotherapy. Expert Opin Biol Ther 2002;2:827-34
   PubMed Web of Science ®Google Scholar
• Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000;101:455-8
   PubMed Web of Science ®Google Scholar
• Curiel TJ, Coukos G, Zou L, Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-9
   PubMed Web of Science ®Google Scholar
• Sato E, Olson SH, Ahn J, Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 2005;102:18538-43
   PubMed Web of Science ®Google Scholar
• Kawaida H, Kono K, Takahashi A, Distribution of CD4+CD25high regulatory T-cells in tumor-draining lymph nodes in patients with gastric cancer. J Surg Res 2005;124:151-7
   PubMed Web of Science ®Google Scholar
• Woo EY, Chu CS, Goletz TJ, Regulatory CD4+CD25+ T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001;61:4766-72
   PubMed Web of Science ®Google Scholar
• Ganesh BB, Cheatem DM, Sheng JR, GM-CSF-induced CD11c+CD8a–dendritic cells facilitate Foxp3+ and IL-10+ regulatory T cell expansion resulting in suppression of autoimmune thyroiditis. Int Immunol 2009;21:269-82
   PubMed Web of Science ®Google Scholar
• Chai JG, Coe D, Chen D, In vitro expansion improves in vivo regulation by CD4+CD25+ regulatory T cells. J Immunol 2008;180:858-69
   PubMed Web of Science ®Google Scholar
• Gaudreau S, Guindi C, Menard M, Granulocyte-macrophage colony-stimulating factor prevents diabetes development in NOD mice by inducing tolerogenic dendritic cells that sustain the suppressive function of CD4+CD25+ regulatory T cells. J Immunol 2007;179:3638-47
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Clark GM, Wong SG, Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82
   PubMed Web of Science ®Google Scholar
• Cobleigh MA, Vogel CL, Tripathy D, Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-48
   PubMed Web of Science ®Google Scholar
• Vogel CL, Cobleigh MA, Tripathy D, Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92
   PubMed Web of Science ®Google Scholar